<p>澳大利亞市場正經歷一些波動，期貨顯示 ASX 200 略有下滑，這主要受到國際貿易不確定性持續影響。儘管出現這些波動，投資者仍在各個領域尋找機會，包括常被忽視的便士股票領域。雖然 “便士股票” 這個術語可能顯得過時，但這些較小或較新的公司在穩健的財務支持下，能夠提供獨特的增長和價值機會。</p>
<h3>澳大利亞十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Lindsay Australia (ASX:LAU)</td>
<td>A$0.71</td>
<td>A$2.2519 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>CTI Logistics (ASX:CLX)</td>
<td>A$1.85</td>
<td>A$1.4901 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Accent Group (ASX:AX1)</td>
<td>A$1.90</td>
<td>A$11.4 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$1.565</td>
<td>A$7383 萬</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.55</td>
<td>A$3.9316 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>GTN (ASX:GTN)</td>
<td>A$0.61</td>
<td>A$1.1642 億</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Bisalloy Steel Group (ASX:BIS)</td>
<td>A$3.50</td>
<td>A$1.6608 億</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Regal Partners (ASX:RPL)</td>
<td>A$2.33</td>
<td>A$7.8326 億</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Tasmea (ASX:TEA)</td>
<td>A$2.99</td>
<td>A$6.9978 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$3.29</td>
<td>A$2.7221 億</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們 ASX 便士股票篩選器的完整 1000 只股票列表。</p>
<p>在這裏，我們突出了一部分我們偏好的股票。</p>
<h2>Aroa Biosurgery (ASX:ARX)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Aroa Biosurgery Limited 開發、製造並銷售用於傷口和軟組織修復的醫療設備，採用細胞外基質技術，市場覆蓋美國及國際，市值為 A$1.759 億。</p>
<p><strong>運營：</strong> 收入細分：Aroa Biosurgery Limited 未報告具體的收入細分。</p>
<p><strong>市值：</strong> A$1.759 億</p>
<p>Aroa Biosurgery 在銷售方面取得了顯著進展，截止 2025 年 3 月 31 日的年度銷售額達到新西蘭元 8470 萬，較去年有所增長。儘管淨虧損為新西蘭元 381 萬，但這標誌着相較於之前虧損的改善。該公司無債務，現金狀況良好，短期資產顯著超過負債，確保了超過三年的穩定財務運行。最近的臨牀證據顯示，其 Endoform Natural 產品在治療靜脈性腿部潰瘍方面的效果優於競爭對手，可能改善患者結果並降低傷口護理管理的成本。</p>
<ul>
<li>點擊探索我們在 Aroa Biosurgery 財務健康報告中的詳細分析。</li>
<li>查看 Aroa Biosurgery 的盈利增長報告，以瞭解分析師對其表現的預期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fa5ec572-df92-499c-a8b8-32f54e806608/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fa5ec572-df92-499c-a8b8-32f54e806608/chart/financial-position-analysis"/></p>
<p>ASX:ARX 財務狀況分析截至 2025 年 6 月</p>
<h2>Baby Bunting Group (ASX:BBN)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Baby Bunting Group Limited 在澳大利亞和新西蘭經營母嬰商品零售，市值為 A$2.3341 億。</p>
<p><strong>運營：</strong> 該公司從其專業零售部門產生 A$4.969 億的收入。</p>
<p><strong>市值：</strong> A$2.3341 億</p>
<p>Baby Bunting Group 的財務狀況複雜，市值為 A$2.3341 億，專業零售部門收入為 A$4.969 億。該公司面臨挑戰，例如過去一年盈利增長為負，利潤率下降，目前為 1.2%。儘管存在這些問題，Baby Bunting 的淨債務與股本比率為 8.6%，且債務由運營現金流 177.9% 良好覆蓋。然而，短期資產無法覆蓋長期負債（A$1.32 億），EBIT 的利息覆蓋率低至 2.2 倍，表明未來可能面臨財務壓力。</p>
<ul>
<li>點擊這裏深入瞭解 Baby Bunting Group 的完整分析健康報告。</li>
<li>在我們的增長報告中探索 Baby Bunting Group 的分析師預測。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4c89021c-58a0-4f55-b9f7-7339012f2ecc/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4c89021c-58a0-4f55-b9f7-7339012f2ecc/chart/revenue-and-expenses-breakdown"/></p>
<p>ASX:BBN 收入與支出分析截至 2025 年 6 月</p>
<h2>COSOL (ASX:COS)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> COSOL Limited 及其子公司在亞太地區、北美、歐洲、中東、非洲及全球提供信息技術服務，市值為 A$1.4286 億。</p>
<p><strong>運營：</strong> 該公司主要從亞太地區運營中產生收入，貢獻 A$9875 萬，北美活動增加 A$1226 萬。</p>
<p><strong>市值：</strong> A$1.4286 億</p>
<p>COSOL Limited 市值為 A$1.4286 億，財務健康狀況複雜。以 16 倍的市盈率交易，並提供高質量的收益，相較於同行具有潛在價值。然而，其短期資產（A$3230 萬）無法覆蓋長期負債（A$4070 萬），淨利潤率從 9.5% 下降至 8.1%。該公司的債務由運營現金流 25% 良好覆蓋，但 3.04% 的股息收益率並未得到自由現金流的支持。最近被納入 S&amp;P/ASX All Ordinaries Index，突顯其在市場上的日益認可。</p>
<ul>
<li>點擊這裏閲讀我們的資產負債表健康報告，深入瞭解 COSOL 的表現。</li>
<li>通過查看我們的增長報告，獲取 COSOL 未來方向的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4ecb08b3-3f0d-4b42-8e82-36db33a9e686/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4ecb08b3-3f0d-4b42-8e82-36db33a9e686/chart/debt-equity-history-analysis"/></p>
<p>ASX:COS 債務與股本歷史分析截至 2025 年 6 月</p>
<h2>讓它發生</h2>
<ul>
<li>點擊這裏，揭示我們 ASX 便士股票篩選器中隱藏的 1,000 個寶藏股票。</li>
<li>準備好不同的投資方式了嗎？特朗普的石油繁榮已經到來——管道準備好獲利。發現 22 只乘風而起的美國股票。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

林賽

<p>澳大利亞市場因國際貿易不確定性面臨 ASX 200 的輕微下跌。投資者正在探索便士股票，這些股票可能提供增長機會。值得注意的便士股票包括 Lindsay Australia、CTI Logistics 和 Aroa Biosurgery，後者儘管出現淨虧損，但銷售增長顯著。Baby Bunting Group 面臨利潤率下降的挑戰，而 COSOL Limited 的財務狀況則表現不一，但在 S&P/ASX All Ordinaries Index 中受到認可。總體而言，便士股票領域仍然是投資者在市場波動中尋求價值的重點</p>

<p>The Australian market is experiencing some turbulence, with futures indicating a slight decline for the ASX 200, largely influenced by ongoing international trade uncertainties. Despite these fluctuations, investors continue to seek opportunities in various sectors, including the often-overlooked realm of penny stocks. Although the term 'penny stocks' might seem outdated, these smaller or newer companies can offer unique opportunities for growth and value when supported by solid financials.</p>
<div class="lb-trans"><p>澳大利亞市場正經歷一些波動，期貨顯示 ASX 200 略有下滑，這主要受到國際貿易不確定性持續影響。儘管出現這些波動，投資者仍在各個領域尋找機會，包括常被忽視的便士股票領域。雖然 “便士股票” 這個術語可能顯得過時，但這些較小或較新的公司在穩健的財務支持下，能夠提供獨特的增長和價值機會。</p>
</div><h3>Top 10 Penny Stocks In Australia</h3>
<div class="lb-trans"><h3>澳大利亞十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Lindsay Australia (ASX:LAU)</td>
<td>A$0.71</td>
<td>A$225.19M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>CTI Logistics (ASX:CLX)</td>
<td>A$1.85</td>
<td>A$149.01M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Accent Group (ASX:AX1)</td>
<td>A$1.90</td>
<td>A$1.14B</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$1.565</td>
<td>A$73.83M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.55</td>
<td>A$393.16M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>GTN (ASX:GTN)</td>
<td>A$0.61</td>
<td>A$116.42M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Bisalloy Steel Group (ASX:BIS)</td>
<td>A$3.50</td>
<td>A$166.08M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Regal Partners (ASX:RPL)</td>
<td>A$2.33</td>
<td>A$783.26M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Tasmea (ASX:TEA)</td>
<td>A$2.99</td>
<td>A$699.78M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$3.29</td>
<td>A$272.21M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Lindsay Australia (ASX:LAU)</td>
<td>A$0.71</td>
<td>A$2.2519 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>CTI Logistics (ASX:CLX)</td>
<td>A$1.85</td>
<td>A$1.4901 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Accent Group (ASX:AX1)</td>
<td>A$1.90</td>
<td>A$11.4 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$1.565</td>
<td>A$7383 萬</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.55</td>
<td>A$3.9316 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>GTN (ASX:GTN)</td>
<td>A$0.61</td>
<td>A$1.1642 億</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Bisalloy Steel Group (ASX:BIS)</td>
<td>A$3.50</td>
<td>A$1.6608 億</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Regal Partners (ASX:RPL)</td>
<td>A$2.33</td>
<td>A$7.8326 億</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Tasmea (ASX:TEA)</td>
<td>A$2.99</td>
<td>A$6.9978 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$3.29</td>
<td>A$2.7221 億</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 1,000 stocks from our ASX Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們 ASX 便士股票篩選器的完整 1000 只股票列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在這裏，我們突出了一部分我們偏好的股票。</p>
</div><h2>Aroa Biosurgery (ASX:ARX)</h2>
<div class="lb-trans"><h2>Aroa Biosurgery (ASX:ARX)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix technology in the United States and internationally, with a market cap of A$175.90 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Aroa Biosurgery Limited 開發、製造並銷售用於傷口和軟組織修復的醫療設備，採用細胞外基質技術，市場覆蓋美國及國際，市值為 A$1.759 億。</p>
</div><p><strong>Operations:</strong> Revenue Segments: No specific revenue segments have been reported for Aroa Biosurgery Limited.</p>
<div class="lb-trans"><p><strong>運營：</strong> 收入細分：Aroa Biosurgery Limited 未報告具體的收入細分。</p>
</div><p><strong>Market Cap:</strong> A$175.9M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$1.759 億</p>
</div><p>Aroa Biosurgery has demonstrated notable progress, with sales reaching NZ$84.7 million for the year ending March 31, 2025, reflecting an increase from the previous year. Despite a net loss of NZ$3.81 million, this marks an improvement from prior losses. The company is debt-free and maintains a strong cash position with short-term assets surpassing liabilities significantly, ensuring a stable financial runway for over three years. Recent clinical evidence highlights the efficacy of its Endoform Natural product in treating venous leg ulcers more effectively than competitors, potentially enhancing patient outcomes and reducing costs in wound care management.</p>
<div class="lb-trans"><p>Aroa Biosurgery 在銷售方面取得了顯著進展，截止 2025 年 3 月 31 日的年度銷售額達到新西蘭元 8470 萬，較去年有所增長。儘管淨虧損為新西蘭元 381 萬，但這標誌着相較於之前虧損的改善。該公司無債務，現金狀況良好，短期資產顯著超過負債，確保了超過三年的穩定財務運行。最近的臨牀證據顯示，其 Endoform Natural 產品在治療靜脈性腿部潰瘍方面的效果優於競爭對手，可能改善患者結果並降低傷口護理管理的成本。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Aroa Biosurgery's financial health report.</li>
<li>Examine Aroa Biosurgery's earnings growth report to understand how analysts expect it to perform.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 Aroa Biosurgery 財務健康報告中的詳細分析。</li>
<li>查看 Aroa Biosurgery 的盈利增長報告，以瞭解分析師對其表現的預期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fa5ec572-df92-499c-a8b8-32f54e806608/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/fa5ec572-df92-499c-a8b8-32f54e806608/chart/financial-position-analysis"/></p>
<p>ASX:ARX Financial Position Analysis as at Jun 2025</p>
<div class="lb-trans"><p>ASX:ARX 財務狀況分析截至 2025 年 6 月</p>
</div><h2>Baby Bunting Group (ASX:BBN)</h2>
<div class="lb-trans"><h2>Baby Bunting Group (ASX:BBN)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Baby Bunting Group Limited operates as a retailer of maternity and baby goods in Australia and New Zealand, with a market cap of A$233.41 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Baby Bunting Group Limited 在澳大利亞和新西蘭經營母嬰商品零售，市值為 A$2.3341 億。</p>
</div><p><strong>Operations:</strong> The company generates A$496.90 million in revenue from its specialty retail segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司從其專業零售部門產生 A$4.969 億的收入。</p>
</div><p><strong>Market Cap:</strong> A$233.41M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$2.3341 億</p>
</div><p>Baby Bunting Group's financial position is mixed, with a market cap of A$233.41 million and revenue of A$496.90 million from its specialty retail segment. The company faces challenges, such as negative earnings growth over the past year and declining profit margins, currently at 1.2%. Despite these issues, Baby Bunting maintains a satisfactory net debt to equity ratio of 8.6%, with debt well covered by operating cash flow at 177.9%. However, short-term assets do not cover long-term liabilities (A$132 million), and interest coverage by EBIT is low at 2.2x, indicating potential financial strain ahead.</p>
<div class="lb-trans"><p>Baby Bunting Group 的財務狀況複雜，市值為 A$2.3341 億，專業零售部門收入為 A$4.969 億。該公司面臨挑戰，例如過去一年盈利增長為負，利潤率下降，目前為 1.2%。儘管存在這些問題，Baby Bunting 的淨債務與股本比率為 8.6%，且債務由運營現金流 177.9% 良好覆蓋。然而，短期資產無法覆蓋長期負債（A$1.32 億），EBIT 的利息覆蓋率低至 2.2 倍，表明未來可能面臨財務壓力。</p>
</div><ul>
<li>Jump into the full analysis health report here for a deeper understanding of Baby Bunting Group.</li>
<li>Explore Baby Bunting Group's analyst forecasts in our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 Baby Bunting Group 的完整分析健康報告。</li>
<li>在我們的增長報告中探索 Baby Bunting Group 的分析師預測。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4c89021c-58a0-4f55-b9f7-7339012f2ecc/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/4c89021c-58a0-4f55-b9f7-7339012f2ecc/chart/revenue-and-expenses-breakdown"/></p>
<p>ASX:BBN Revenue &amp; Expenses Breakdown as at Jun 2025</p>
<div class="lb-trans"><p>ASX:BBN 收入與支出分析截至 2025 年 6 月</p>
</div><h2>COSOL (ASX:COS)</h2>
<div class="lb-trans"><h2>COSOL (ASX:COS)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> COSOL Limited, along with its subsidiaries, offers information technology services across the Asia Pacific, North America, Europe, the Middle East, Africa, and globally with a market cap of A$142.86 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> COSOL Limited 及其子公司在亞太地區、北美、歐洲、中東、非洲及全球提供信息技術服務，市值為 A$1.4286 億。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its Asia Pacific operations, contributing A$98.75 million, and North American activities, adding A$12.26 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要從亞太地區運營中產生收入，貢獻 A$9875 萬，北美活動增加 A$1226 萬。</p>
</div><p><strong>Market Cap:</strong> A$142.86M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$1.4286 億</p>
</div><p>COSOL Limited, with a market cap of A$142.86 million, demonstrates mixed financial health. Trading at a value price-to-earnings ratio of 16x and offering high-quality earnings, it presents potential value compared to peers. However, its short-term assets (A$32.3M) do not cover long-term liabilities (A$40.7M), and net profit margins have declined from 9.5% to 8.1%. The company's debt is well covered by operating cash flow at 25%, but the dividend yield of 3.04% isn't supported by free cash flows. Recent inclusion in the S&amp;P/ASX All Ordinaries Index highlights its growing recognition in the market.</p>
<div class="lb-trans"><p>COSOL Limited 市值為 A$1.4286 億，財務健康狀況複雜。以 16 倍的市盈率交易，並提供高質量的收益，相較於同行具有潛在價值。然而，其短期資產（A$3230 萬）無法覆蓋長期負債（A$4070 萬），淨利潤率從 9.5% 下降至 8.1%。該公司的債務由運營現金流 25% 良好覆蓋，但 3.04% 的股息收益率並未得到自由現金流的支持。最近被納入 S&amp;P/ASX All Ordinaries Index，突顯其在市場上的日益認可。</p>
</div><ul>
<li>Get an in-depth perspective on COSOL's performance by reading our balance sheet health report here.</li>
<li>Gain insights into COSOL's future direction by reviewing our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏閲讀我們的資產負債表健康報告，深入瞭解 COSOL 的表現。</li>
<li>通過查看我們的增長報告，獲取 COSOL 未來方向的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4ecb08b3-3f0d-4b42-8e82-36db33a9e686/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/4ecb08b3-3f0d-4b42-8e82-36db33a9e686/chart/debt-equity-history-analysis"/></p>
<p>ASX:COS Debt to Equity History and Analysis as at Jun 2025</p>
<div class="lb-trans"><p>ASX:COS 債務與股本歷史分析截至 2025 年 6 月</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>讓它發生</h2>
</div><ul>
<li>Reveal the 1,000 hidden gems among our ASX Penny Stocks screener with a single click here.</li>
<li>Ready For A Different Approach? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏，揭示我們 ASX 便士股票篩選器中隱藏的 1,000 個寶藏股票。</li>
<li>準備好不同的投資方式了嗎？特朗普的石油繁榮已經到來——管道準備好獲利。發現 22 只乘風而起的美國股票。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

2025 年 6 月值得關注的 ASX 便士股